Stockscreener 앱 받기
0.898
0.14%
-0.0013
시간 외 거래:
.88
-0.018
-2.00%
Imunon Inc 주식(IMNN)의 최신 뉴스
Imunon director Donald Braun acquires $29,480 worth of shares - MSN
Imunon’s (IMNN) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Analyzing Imunon (NASDAQ:IMNN) & Unicycive Therapeutics (NASDAQ:UNCY) - Defense World
IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer - GlobeNewswire
IMUNON Secures FDA Alignment for Phase 3 Ovarian Cancer Immunotherapy Manufacturing Strategy - StockTitan
Imunon, Inc. (NASDAQ:IMNN) Short Interest Update - Defense World
IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001 - The Manila Times
IMUNON Announces Continued Strong Improvement in Overall - GlobeNewswire
IMUNON's Ovarian Cancer Drug Shows Improved Survival Data in Phase 2 Trial, Phase 3 Planned - StockTitan
Critical Review: Sernova (OTCMKTS:SEOVF) & Imunon (NASDAQ:IMNN) - Defense World
Imunon faces Nasdaq delisting over share price rule By Investing.com - Investing.com Canada
Imunon faces Nasdaq delisting over share price rule - Investing.com
D. Boral Capital Reaffirms Buy Rating for Imunon (NASDAQ:IMNN) - Defense World
Imunon shares hold as analyst backs stock target, buy rating post FDA meet - Investing.com UK
IMNN: Comes to Alignment with FDA Regarding Phase 3 Protocol for IMNN-001 - Smartkarma
Imunon announces results from End-of-Phase 2 meeting with FDA for IMNN-001 - TipRanks
IMUNON Announces Results from its End-of-Phase 2 Meeting - GlobeNewswire
IMUNON's Cancer Drug Shows 35% Survival Boost, FDA Backs Phase 3 Trial | IMNN Stock News - StockTitan
FY2024 EPS Estimates for Imunon Boosted by Zacks Small Cap - Defense World
Analysts Set Expectations for Imunon Q1 Earnings - Defense World
Imunon, Inc. (NASDAQ:IMNN) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Imunon reveals promising ovarian cancer study results - Investing.com India
Earnings call: Imunon reveals promising ovarian cancer study results By Investing.com - Investing.com UK
Imunon Inc (IMNN) Q3 2024 Earnings Call Highlights: Promising Clinical Advances Amid Financial ... - Yahoo Finance
Imunon, Inc. Reports Q3 2024 Earnings and Progress - TipRanks
Imunon Inc (IMNN) Quarterly 10-Q Report - Quartzy
Imunon presents data from Phase 2 OVATION 2 clinical trial - TipRanks
IMUNON Presents Positive Data from Phase 2 OVATION 2 - GlobeNewswire
IMUNON's Cancer Drug Shows 35% Survival Boost in Phase 2 Ovarian Cancer Trial | IMNN Stock News - StockTitan
Imunon sees cash runway into 3Q25 - TipRanks
IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
IMUNON INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Imunon (IMNN) to Release Quarterly Earnings on Thursday - MarketBeat
IMUNON to Hold Third Quarter 2024 Financial Results and - GlobeNewswire
IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024 - Yahoo Finance
IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of - GlobeNewswire
IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting - Marketscreener.com
IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting - Yahoo Finance
Imunon’s stock rockets after ovarian cancer treatment’s positive trial results - MSN
Imunon reports inducement grant under NASDAQ listing rule - Yahoo Finance
Ex-Allstate Atty Named Biotech Co.'s General Counsel - Law360
Imunon Welcomes Susan Eylward as General Counsel, Strengthens Leadership Team - TipRanks
IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary - Marketscreener.com
Imunon (NASDAQ:IMNN) Upgraded by EF Hutton Acquisition Co. I to “Strong-Buy” - Defense World
Imunon (NASDAQ:IMNN) Upgraded to "Strong-Buy" at EF Hutton Acquisition Co. I - MarketBeat
EF Hutton sets stock target on Imunon, initiates with buy rating - Investing.com Canada
Ratio Review: Analyzing Imunon Inc (IMNN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
1.03%
자본화:
|
볼륨(24시간):